Find, compare & contact
Zuclopenthixol
API Manufacturers & Suppliers
India
Bangladesh
Brazil
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Zuclopenthixol API 53772-83-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Zuclopenthixol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Zuclopenthixol
- Synonyms:
- cis-Clopenthixol , Zuclopenthixolum , Zuclopentixol , Cisordinol
- Cas Number:
- 53772-83-1
- DrugBank number:
- DB01624
- Unique Ingredient Identifier:
- 47ISU063SG
About Zuclopenthixol
Here, you can find what Zuclopenthixol is used for, in short. Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Zuclopenthixol is a type of Classic antipsychotics
Classic antipsychotics, also known as first-generation antipsychotics (FGAs), are a prominent subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of psychiatric disorders. These medications are primarily prescribed to manage symptoms associated with conditions such as schizophrenia and bipolar disorder.
Classic antipsychotics work by blocking dopamine receptors in the brain, which helps to alleviate symptoms like hallucinations, delusions, and disorganized thinking. Some commonly used classic antipsychotics include chlorpromazine, haloperidol, and fluphenazine.
These APIs exert their therapeutic effects by antagonizing dopamine D2 receptors, thereby reducing the activity of this neurotransmitter in specific brain regions. This mechanism helps to restore the delicate balance of dopamine and other neurotransmitters, leading to an improvement in symptoms of psychosis.
Despite being the first generation of antipsychotics developed, classic antipsychotics still have a significant role in modern medicine. However, their use has somewhat declined due to the advent of second-generation antipsychotics (SGAs) that offer a more favorable side effect profile. Nonetheless, classic antipsychotics remain an essential treatment option, particularly in situations where SGAs may be contraindicated or ineffective.
It is crucial to note that the use of classic antipsychotics requires careful monitoring due to potential side effects, such as extrapyramidal symptoms (EPS), sedation, and tardive dyskinesia. Physicians must assess the risk-benefit ratio and tailor the treatment approach to each patient's specific needs.
In summary, classic antipsychotics represent a notable subcategory of pharmaceutical APIs utilized in the treatment of psychiatric disorders. While their usage has somewhat declined, they continue to play a vital role in managing symptoms associated with conditions like schizophrenia, providing valuable options for healthcare providers and patients alike.
Zuclopenthixol (Classic antipsychotics), classified under Antipsychotics
Antipsychotics belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category used to treat psychiatric disorders such as schizophrenia, bipolar disorder, and other related conditions. These medications play a crucial role in managing symptoms associated with psychosis, including hallucinations, delusions, and disorganized thinking.
Antipsychotics work by modulating the levels of neurotransmitters in the brain, particularly dopamine and serotonin. They can be categorized into two classes: first-generation (typical) antipsychotics and second-generation (atypical) antipsychotics. Typical antipsychotics primarily target dopamine receptors, while atypical antipsychotics also affect serotonin receptors.
The pharmaceutical API category of antipsychotics includes various well-known drugs, such as haloperidol, chlorpromazine, risperidone, quetiapine, and olanzapine. These APIs are often formulated into different dosage forms, including tablets, capsules, injections, and oral suspensions, to provide flexibility in administration and patient-specific needs.
Antipsychotics offer relief from psychotic symptoms by stabilizing the imbalanced neurotransmitter activity in the brain. However, they may also have certain side effects, such as sedation, weight gain, extrapyramidal symptoms, and metabolic disturbances. It is essential for healthcare professionals to carefully monitor patients receiving antipsychotic treatment to optimize therapeutic benefits while minimizing adverse effects.
In summary, antipsychotics are a vital category of pharmaceutical APIs used to manage psychiatric disorders by modulating neurotransmitter activity in the brain. Their effectiveness in treating psychosis has made them a cornerstone of mental health treatment, providing much-needed relief to individuals suffering from these conditions.
